Thursday, Angel Biotechnology Holdings Plc (ABH.L) said it is signing a contract with ReNeuron Group Plc. The contract is to perform work to further develop and manufacture clinical-grade lots of a second-generation formulation of ReNeuron's lead CTX stem cell line, for subsequent pre-clinical and clinical applications. The value of the contract was not disclosed, the company said.
"As ReNeuron's manufacturing partner, Angel will be manufacturing the stem cell clinical product for their previously announced first-in-man Phase I clinical trial for stroke. We are very pleased to have been chosen by ReNeuron to further develop and manufacture the second generation formulation of their CTX neural stem cell line for subsequent pre-clinical and clinical applications. Provision of the highest quality support for such advanced biological therapies is Angel's core competence and this contract firmly places Angel in the vanguard of this important and exciting development in medicinal therapy," said Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings Plc.
For comments and feedback: editorial@rttnews.com